NovaBay^® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company
focusing on the development and commercialization of its non-antibiotic
anti-infective products, today announced that it has signed an exclusive
distribution agreement for NovaBay's NeutroPhase^® Skin and Wound Cleanser
with the Biopharm Group, a leading pharmaceutical company in the Middle East,
headquartered in Cairo, Egypt.
NeutroPhase with Neutrox (Photo: Business Wire)
NeutroPhase with Neutrox (Photo: Business Wire)
Under the terms of the agreement, Biopharm will market NeutroPhase in Egypt,
Saudi Arabia, Algeria, Sudan and Libya.
Saudi Arabia, in particular, is a large potential market for NeutroPhase. The
nation's per capita income is $51,800—more than $8500 higher than Canada's—and
its rates of chronic diseases like diabetes are rising. The increase in
chronic diseases, in turn, means a higher rate of medical problems like
diabetic ulcers, for which NeutroPhase is an FDA-cleared adjunct treatment. In
fact, researchers report that the number of lower limb amputations due to
unhealed diabetic ulcers in Saudi Arabia is climbing rapidly. More effective
treatments for those wounds could save those limbs—while also lowering overall
medical costs.
“NeutroPhase can make a major difference to patients in countries like Saudi
Arabia,” said Dr. Ron Najafi, Chairman and CEO of NovaBay. “With the help of
Biopharm's experienced team, we will be able to reach those patients and their
doctors. The agreement reflects our overall strategy of making our products
available to patients around the globe, following on similar agreements that
make NeutroPhase available in the US and international markets in China, South
Korea, and Southeast Asia.”
“We are pleased to partner with NovaBay because we believe that NeutroPhase
can enhance management of chronic wounds, especially diabetic foot ulcers,
prevalent in Saudi Arabia and the rest of the Middle East North Africa
region,” added Dr. Osama Kandil, Chairman and CEO of Biopharm.
NovaBay's FDA-cleared NeutroPhase has shown success in the management of
chronic wounds, such as diabetic ulcers. As cited in a paper published in the
peer-reviewed International Journal of Burns and Trauma, “Patients showed a
profound improvement after treatment with NeutroPhase, both with and without
NPWT (negative pressure wound therapy). NeutroPhase was shown to be non-toxic
to living tissues.”
NeutroPhase is the only skin and wound care product to contain Neutrox^™,
NovaBay's patented and proprietary pure hypochlorous acid (HOCl). Laboratory
tests show that Neutrox, which is chemically identical to a naturally
occurring substance released by white blood cells to fight microbial invaders,
has potent antimicrobial activity, yet is non-toxic to normal healthy cells.
Laboratory tests also demonstrate that Neutrox neutralizes bacterial toxins,
and has been cleared by the Food & Drug Administration to clean skin and
wounds as well as for the management of pressure, diabetic and venous stasis
ulcers that can seriously affect a patient's morbidity and mortality.
NeutroPhase has also been used successfully as part of a new treatment regimen
to save the lives and limbs of victims of life-threatening flesh-eating
disease, as Dr. John Crew, director of the Advanced Wound Care Center at Seton
Medical Center in Daly City, Calif., and NovaBay researchers reported in the
journal WOUNDS.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in